MDGL
Madrigal Pharmaceuticals, Inc.
NASDAQ · USHealthcareBiotechnology
$535.69-3.21%
Price as of Jul 20, 2026
MDGL profitability
Madrigal Pharmaceuticals, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 93.1%
- EBITDA margin
- -24.8%
- EBIT margin
- -27.7%
- Net margin
- -27.3%
- Free cash flow margin
- -24.1%
Returns
- Return on equity
- -56.9%
- Return on assets
- -25.2%
- Return on invested capital
- -35.2%
- Asset turnover
- 0.91x
Cash efficiency
- Cash from operations
- -$268.1M
- Cash per share
- $35
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.